Compare · BDX vs ZIMV
BDX vs ZIMV
Side-by-side comparison of Becton Dickinson and Company (BDX) and ZimVie Inc. (ZIMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and ZIMV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX carries a market cap of $41.33B.
- Over the past year, BDX is down 13.0% and ZIMV is up 101.9% - ZIMV leads by 114.9 points.
- BDX has hit the wire 10 times in the past 4 weeks while ZIMV has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 9 for ZIMV).
- Company
- Becton Dickinson and Company
- ZimVie Inc.
- Price
- $150.14-0.71%
- $18.99+0.00%
- Market cap
- $41.33B
- -
- 1M return
- -2.01%
- +0.37%
- 1Y return
- -12.95%
- +101.91%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest ZIMV
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- SEC Form 15-12G filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by ZimVie Inc.
- Amendment: SEC Form 25-NSE/A filed by ZimVie Inc.
- Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Asar Vinit K
- Officer Kidwell Heather returned 83,674 shares to the company, closing all direct ownership in the company (SEC Form 4)